Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Indivior Pharmaceuticals (INDV) Long-Term Deferred Tax (2021 - 2025)

Indivior Pharmaceuticals (INDV) has 3 years of Long-Term Deferred Tax data on record, last reported at $277.0 million in Q4 2024.

  • For Q4 2024, Long-Term Deferred Tax fell 3.15% year-over-year to $277.0 million; the TTM value through Dec 2024 reached $277.0 million, down 3.15%, while the annual FY2024 figure was $277.0 million, 3.15% down from the prior year.
  • Long-Term Deferred Tax reached $277.0 million in Q4 2024 per INDV's latest filing, down from $286.0 million in the prior quarter.
  • Across five years, Long-Term Deferred Tax topped out at $286.0 million in Q4 2023 and bottomed at $219.0 million in Q4 2022.
  • Average Long-Term Deferred Tax over 3 years is $260.7 million, with a median of $277.0 million recorded in 2024.
  • Peak YoY movement for Long-Term Deferred Tax: skyrocketed 30.59% in 2023, then fell 3.15% in 2024.
  • A 3-year view of Long-Term Deferred Tax shows it stood at $219.0 million in 2022, then skyrocketed by 30.59% to $286.0 million in 2023, then fell by 3.15% to $277.0 million in 2024.
  • Per Business Quant database, its latest 3 readings for Long-Term Deferred Tax were $277.0 million in Q4 2024, $286.0 million in Q4 2023, and $219.0 million in Q4 2022.